GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » EV-to-FCF

Response Genetics (Response Genetics) EV-to-FCF : 0.00 (As of Jun. 20, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Response Genetics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Response Genetics's Enterprise Value is $0.00 Mil. Response Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2015 was $-12.58 Mil. Therefore, Response Genetics's EV-to-FCF for today is 0.00.

The historical rank and industry rank for Response Genetics's EV-to-FCF or its related term are showing as below:

RGDXQ's EV-to-FCF is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 24.13
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-20), Response Genetics's stock price is $0.0001. Response Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2015 was $-0.360. Therefore, Response Genetics's PE Ratio for today is At Loss.


Response Genetics EV-to-FCF Historical Data

The historical data trend for Response Genetics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Response Genetics EV-to-FCF Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.40 -4.21 -4.52 0.46 0.88

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Response Genetics's EV-to-FCF

For the Diagnostics & Research subindustry, Response Genetics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Response Genetics's EV-to-FCF falls into.



Response Genetics EV-to-FCF Calculation

Response Genetics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=0.000/-12.584
=0.00

Response Genetics's current Enterprise Value is $0.00 Mil.
Response Genetics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Response Genetics  (OTCPK:RGDXQ) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Response Genetics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-0.360
=At Loss

Response Genetics's share price for today is $0.0001.
Response Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.360.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Response Genetics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Response Genetics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Response Genetics (Response Genetics) Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Executives
Roberto Mignone 10 percent owner C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber director 15 TROTTERS LANE, MONROE CT 06468
Sam Chawla director 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris officer: Vice President and CFO 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya director C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna director, officer: Chief Executive Officer 4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics (Response Genetics) Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor 12-14-2009